Biofrontera Inc. BFRI

What this company does

Biofrontera Inc. is a United States based biopharmaceutical company engaging in the development, manufacturing, and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamp series, are used for the treatment of actinic keratosis, a common skin condition characterized by the growth of pre-cancerous lesions. With its national commercial team, the company generates revenue by selling its products directly to dermatology offices and groups. The company was formed in 2015 as Biofrontera Inc., a Delaware corporation, and a wholly owned subsidiary of Biofrontera AG, a stock corporation organized under the laws of Germany. In 2021, the company completed its initial public offering. On October 20, 2025, the company entered into an Asset Purchase Agreement and an Earnout Agreement with the Biofrontera Group, pursuant to which the Company acquired all rights in the United States to Ameluz and RhodoLED. As of December 31, 2025, the Company had a total of 92 employees, comprised of 75 employees in the United States and 19 employees located in Germany.

Written from the business description in Biofrontera Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 19 March 2026. Every sentence was checked against that document before publication.